Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and S-1 in Residual Node-Negative Esophageal Squamous Cell Carcinoma
NCT06354140Phase 2Recruiting
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Started May 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06354140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354140.